Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies

BACKGROUND: This report summarizes three phase I studies evaluating volasertib, a polo-like kinase inhibitor, plus azacitidine in adults with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia. METHODS: Patients received intravenous volasertib in 28-day cycle...

Descripción completa

Detalles Bibliográficos
Autores principales: Platzbecker, Uwe, Chromik, Joerg, Krönke, Jan, Handa, Hiroshi, Strickland, Stephen, Miyazaki, Yasushi, Wermke, Martin, Sakamoto, Wataru, Tachibana, Yoshifumi, Taube, Tillmann, Germing, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124414/
https://www.ncbi.nlm.nih.gov/pubmed/35597904
http://dx.doi.org/10.1186/s12885-022-09622-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124414/
https://www.ncbi.nlm.nih.gov/pubmed/35597904
http://dx.doi.org/10.1186/s12885-022-09622-0

Ejemplares similares